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ABSTRACT 
Agitation associated with dementia is frequently reported clinically but has received little 
attention in preclinical models of dementia. The current study used a 7PA2 CM 
intracerebroventricular (ICV) injection model of Alzheimer’s disease (AD) to assess acute 
memory impairment, and a bilateral intrahippocampal (IH) injection model of AD 
(aggregated Aβ1-42 injections) and a bilateral IH injection model of dementia with Lewy 
bodies (DLB; aggregated NAC61-95 injections) to assess chronic memory impairment in the 
rat. An alternating-lever cyclic-ratio schedule of operant responding was employed for data 
collection, where incorrect lever perseverations measured executive function (memory) and 
running response rates (RRR) measured behavioral output (agitation). The results indicate 
that bilateral IH injections of Aβ1-42 and bilateral IH injections of NAC61-95 decreased 
memory function and increased RRRs, whereas ICV injections of 7PA2 CM decreased 
memory function but did not increase RRRs. These findings show that using the aggregated 
peptide IH injection models of dementia to induce chronic neurotoxicity, memory decline 
was accompanied by elevated behavioral output. This demonstrates that IH peptide injection 
models of dementia provide a preclinical screen for pharmacological interventions used in the 
treatment of increased behavioral output (agitation), that also establish detrimental side 
effects on memory. 
 
 
Key Words: Alzheimer’s disease; dementia with Lewy bodies; agitation; memory; animal 
model; pharmacotherapy. 
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INTRODUCTION 
A significant number of patients suffering from dementia exhibit behaviors indicative 
of agitation (Savva et al., 2009; Ryu et al., 2005) such as restlessness and disturbed sleep 
(Cipriani et al., 2014), and it has been estimated that approximately 90% of dementia 
sufferers develop behavioral problems that supersede the seminal symptom of memory 
dysfunction (Tariot and Blazina, 1993). Agitation is found in Alzheimer’s disease (AD), 
dementia with Lewy bodies (DLB), frontotemporal dementia, and other syndromes resulting 
in dementia (Burns and Josephs, 2013; Manoochehri and Huey, 2012; Ballard and Corbett, 
2010). Agitation has been defined as inappropriate verbal, vocal or motor activity that is 
unexplained by apparent needs or confusion (Cohen-Mansfield and Billig, 1986).  While 
agitation might include aggressive behaviors, it can occur without aggression (Cummings et 
al., 2015), and when it is severe it requires pharmacological treatment (Herrmann and 
Lanctot, 2007). The treatment of agitation has been identified as an unmet need in relation to 
adequate care provided for those suffering from cognitive impairments (Gitlin et al., 2012; 
Herrmann and Lanctot, 2007). When the agitation is severe the symptoms include 
disinhibition, irritability, aggression and aberrant motor activity, which affect the patient’s 
quality of life and cause increased stress for the family and caregivers (Antonsdottir et al., 
2015; Cummings et al., 2015; Panza et al., 2015; Kales et al., 2014). 
This aspect of dementia has been largely overlooked in the employment of laboratory-
based animal models of dementia, where the focus has been directed toward establishing 
neuropathological and behavioral features reflecting a decline in memory abilities. Agitation 
related to dementia is frequently observed clinically (Cohen-Mansfield, 2013; Ballard et al., 
2001; Lyketsos et al., 2000), and various pharmacological interventions have been employed 
to treat this. These treatments include the use of anxiolytic, antidepressant, antipsychotic and 
anticonvulsant drugs (Antonsdottir et al., 2015; Cummings et al., 2015; Panza et al., 2015; 
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Soto et al., 2015; Kales et al., 2014; Salzman et al., 2008). The most contentious approach 
relates to the use of antipsychotic drugs (Jeste et al., 2008), which have been reported to be of 
only modest value (Ballard et al., 2009; Schneider et al., 2006), and to produce adverse 
effects (Gitlin et al., 2012). Overall, the currently available pharmacological treatments for 
agitation in dementia are of little value, and the adverse effects of antipsychotic drugs are of 
considerable concern (Sacchetti et al., 2012; Ma et al., 2014; Ballard, 2006; Schneider et al., 
2006). Basically, there are no officially approved pharmacotherapies for agitation in 
dementia, and few if any safe and effective pharmacotherapies (Antonsdottir et al., 2015; 
Cummings et al., 2015; Panza et al., 2015; Soto et al., 2015; Kales et al., 2014; Salzman et 
al., 2008). Also, non-pharmaceutical approaches have been shown to be of very limited value 
(Ballard et al., 2016; Steinberg, 2016; Kales et al., 2014). Of the pharmacological treatments 
used for the management of agitation in dementia, benzodiazepines (anxiolytics) have weak 
effects (Defrancesco et al., 2015; Ngo and Holroyd-Leduc, 2015; Kales et al., 2014; Wilson 
et al., 2012; Salzman et al., 2008) and have been found to accelerate cognitive deterioration 
(Defrancesco et al., 2015), the antidepressants citalopram (Pollock et al., 2002) and sertraline 
(Lyketsos et al., 2003) have been suggested to have some effects (Sink et al., 2005), however 
the trial using citalopram had a high dropout rate due to lack of efficacy and sertraline had no 
benefit with respect to neuropsychiatric symptoms. Antipsychotics are of modest value 
(Gitlin et al., 2012; Ballard et al., 2009) but induce adverse cerebrovascular events, especially 
during the first weeks of treatment (Wu et al., 2013; Sacchetti et al., 2012) and increase 
mortality (Ma et al., 2014; Sacchetti et al., 2012; Ballard, 2006; Schneider et al., 2006), and 
anticonvulsants raise concerns with respect to tolerability (Gallagher and Herrmann, 2014). 
Consequently, a preclinical model of dementia that measures adverse effects on memory (the 
seminal symptom of dementia), and also models the agitation commonly observed clinically, 
would be useful for screening pharmacotherapies for the treatment of agitation in dementia. 
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The widely known form of dementia is AD, which is associated with the 
accumulation of amyloid-β (Aβ) plaques in the brain (e.g., Glenner and Wong, 1984). It 
accounts for up to 80% of all cases of dementia (Herbert et al., 2013) and is comprehensively 
documented. DLB is the second most common form of dementia, it presents in approximately 
40% of Parkinson’s disease cases (Poewe, 2005), and the severity of DLB correlates 
significantly with the density of Lewy body (LB) deposition in the brain (Hurtig et al., 2000). 
While Aβ1-42 (the most toxic form of Aβ) and Aβ1-40 are major components of the aggregated 
plaques found in AD, aggregated α-synuclein is the major component of LBs (Spillantini et 
al., 1998), and the non-amyloid component (NAC) region of α-synuclein, residues 61-95 
(NAC61-95), is essential for the aggregation and toxicity of α-synuclein (El-Agnaf et al., 
1998). NAC61-95 was first isolated from the amyloid plaques associated with AD (Ueda et al., 
1993), and this region of α-synuclein has been linked with an increased propensity of α-
synuclein to form fibrils (Jethva et al., 2011). The fibrillogenic capacity of NAC61-95 is well 
documented, and the extracellular aggregation of NAC and intracellular accumulation of α-
synuclein are considered to be contributory factors in the pathogenesis of DLB and AD. 
Consequently, to determine whether an animal model of dementia can reflect the 
increased behavioral output (agitation) commonly reported in clinical observations of patients 
suffering from dementia, the current study employed a bilateral intrahippocampal (IH) 
injection model of the effect of aggregated Aβ1-42 in AD, and a bilateral IH injection model of 
the effect of aggregated NAC61-95 in DLB to produce chronic neurotoxic peptide deposits in 
the brain. While recent theories relating to the onset of dementia, and in particular AD, 
suggest that the precipitating event is the disruption of synaptic transmission due to the 
formation of the oligomeric configuration of the neurotoxic peptide (e.g., Ondrejcak et al., 
2010; Pharm et al., 2010; Klyubin et al., 2008; Shankar et al., 2008; Haas and Selkoe, 2007; 
Walsh and Selkoe, 2007), very few patients presenting clinically with symptoms of memory 
6 
 
 
 
decline are likely to be at such an early stage of disease progression. However, the 
intracerebroventricular (ICV) 7PA2 CM injection model of AD (e.g., Cleary et al., 2005) was 
employed to determine the effects of acute synaptotoxicity on increased behavioral output, 
even though clinical management of typical dementia cases generally involves the use of 
drugs for the treatment of agitation following diagnosis at the stage of pathogenesis when 
aggregated neurotoxic peptides are chronically established in the brain. 
The operant technique employed was the alternating-lever cyclic-ratio (ALCR) 
schedule (Weldon et al., 1996). This experimental evaluation of behavior has been used to 
assess the effects of bilateral IH injections of aggregated Aβ1-42 (Richardson et al., 2002; 
O’Hare et al., 1999), bilateral IH injection of aggregated NAC61-95 (O’Hare et al., 2010a,b; 
Kim et al., 2009), and ICV injections of 7PA2 CM in the rat (e.g., Poling et al., 2008; Cleary 
et al., 2005). The aggregated peptide injections were delivered into the hippocampus as this is 
an area of the brain directly implicated in learning and memory (Jerrard, 1993), and the 
ALCR schedule was used as this is recognized as a sensitive, accurate and parsimonious 
determinant of memory function in the rat (Poling et al., 2008; Cleary et al., 2005). Also, the 
ALCR provides data indicating experimental effects on running response rates (RRRs). RRRs 
illustrate increases or decreases in behavioral output, and increased RRRs may be analogous 
to the increased behavioral output seen as agitation in human dementia. 
The RRR is the rate of lever press responding at any given operant ratio response 
value, minus the post-reinforcement pause duration (Ferster and Skinner, 1957). The post-
reinforcement pause duration is the time spent after receiving a reinforcer (generally a food 
pellet for experimental animals) prior to beginning the next lever press engagement for 
production of the next reinforcer. Consequently, RRRs provide a measure of actual lever 
pressing activity per unit of lever pressing time. This observation is generally incorporated in 
operant experiments to ensure that malaise or peripheral motor impedance resulting from an 
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experimental manipulation is not misinterpreted as an adverse central nervous system effect 
on memory-related behavioral measurements. That is, an observed decline in cognitive 
(memory) ability that correlates with a reduction in RRRs might simply be a reflection of the 
physical inability of an animal, due to malaise or illness, to complete a required task (seen as 
a decrease in activity, and misinterpreted as an effect on memory). In the current study, data 
on RRRs were collected to determine whether the induction of neurotoxicity might affect 
RRRs in a manner that indicated the development of agitation. These data were used to 
determine whether an increase in RRRs, possibly inferring the agitation commonly seen in 
the syndrome reported for human patients suffering from dementia, was an inherent feature of 
experimentally-induced memory dysfunction due to acute synaptotoxicity (ICV 7PA2 CM 
injections), or chronic neurotoxicity due the presence of neurotoxic peptide aggregates in the 
hippocampal region of the brain. 
 
METHODS 
Subjects 
Forty eight male Sprague-Dawley rats (Harlan, UK), weighing 229-250 g at the beginning of 
the experiment were maintained at 90% of their free-feeding body weights, and housed 
individually with water available ad libitum in the home cage. The temperature in the 
vivarium was maintained at 23ºC under a 12 h light/12 h dark cycle (lights on at 0800 h). The 
relative humidity of the vivarium was maintained at 50-65%, and light intensity was 
controlled at a maximum of 9 lux in the home cage. This work was approved by the relevant 
institutional ethics committees and conducted under Home Office License (UK). 
 
Apparatus 
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Ten two-lever rat test chambers (Med Associates Inc, St Albans, NJ, USA) enclosed in sound 
attenuating compartments were employed. Food reinforcers were 45 mg sucrose food pellets 
(BioServ, Frenchtown, NJ, USA) that were delivered into a tray situated midway between the 
two operant levers. A Siemens computer programmed in MED-PC (Med Associates Inc, St 
Albans, NJ, USA) controlled the experiment and collected data. The operant test cambers had 
internal dimensions of 30.5 cm long x 24.1 cm wide x 21 cm high, the pellet receptacle was 
2.9 cm wide x 2.5 cm high x 1.9 cm deep, and was situated in the center of the 24.1 cm 
chamber wall. The retractable operant response levers were 4.8 cm wide x 1.9 cm deep and 
were positioned 2.1 cm above the floor of the chamber on each side of the pellet receptacle. 
The house light was situated in the center of the chamber ceiling, and when illuminated had 
an output of 3 W. 
 
Behavioral training 
The training procedure employed has previously been reported extensively (e.g., Cleary et al., 
2005; Richardson et al., 2002; Weldon et al., 1996). Briefly, behavioral sessions were 
conducted 7 d/wk, during which the rats were trained to press both levers for food 
reinforcement, each operant training session lasted for a maximum of 50 min. Over 
approximately 20-30 sessions following initial lever press training, the ALCR schedule was 
introduced. Using this schedule, rats alternate to the other lever after pressing the currently 
correct lever a sufficient number of times to obtain a food reinforcer. The number of lever 
presses required for each reinforcer changes, increasing from 2 responses per food pellet up 
to 56 responses per food pellet, and then decreasing back to 2 responses per food pellet, 
repeated over 6 cycles. One complete cycle requires alternating-lever responses of 2, 6, 12, 
20, 30, 42, 56, 56, 42, 30, 20, 12, 6 and 2. This generates data on incorrect lever 
perseverations, which indicate disruption of well-learned behaviors, or reference memory, 
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including general aspects of executive function, reasoning, and goal-oriented manipulation of 
previously acquired information (Poling et al., 2008; Cleary et al., 2005). The ALCR 
schedule also measures RRRs; these are response rates at each schedule value, minus the 
post-reinforcement pause duration. Consequently, RRRs provide a measure of actual lever 
pressing activity per unit of lever pressing time, thereby indicating the general level of 
activity. 
 
7PA2 Conditioned Medium 
7PA2 cells are stably transfected Chinese hamster ovary cells which incorporate the cDNA 
for amyloid precursor protein (APP751), this is specific for the familial AD mutation 
Val171Phe (Shankar et al., 2011; Podlisny et al., 1998). These cells secrete Aβ1-40 and Aβ1-42 
(Shankar et al., 2011), and were grown to just below confluence in DMEM containing 10% 
FBS and 200 µg/ml G418. They were briefly washed in DPS and incubated at 37ºC with 5% 
CO2 for 18 h with a sufficient volume of DMEM to cover the cells. After incubation the 
medium was centrifuged at 3000 g for 15 min and snap frozen and stored at -20ºC until 
thawing for ICV injections. Using ELISA, the concentration of total Aβ in the 7PA2 CM was 
in the range of 2-5 nM. 
 
Aggregation of Aβ1-42 and NAC61-95 
Aggregated Aβ1-42 and aggregated NAC61-95 were prepared from solutions of 10-4 M soluble 
Aβ1-42 or soluble NAC61-95 peptides (Sigma, UK) in 0.01 M filtered phosphate buffered saline 
(PBS; pH 7.4) (Weldon et al., 1998). The Aβ1-42 and NAC61-95 solutions were agitated 
(Teflon-coated stirbar at 200 rpm) at room temperature for 36 h. Following agitation, both 
solutions (Aβ1-42 and NAC61-95) were turbid. The Aβ1-42 and NAC61-95 peptides were then 
sedimented by centrifugation (10 min X 15,000 g) to 80% sedimentation of each peptide. 
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These sediments of aggregated Aβ1-42 and aggregated NAC61-95 were then dissolved with 
PBS, aliquoted and stored at -20ºC prior to thawing for bilateral IH injections. 
 
Surgical procedure 
When all rats were capable of completing the ALCR schedule in 50 min without 
demonstrating changes in operant response trends, they were anaesthetized with fentanyl 
citrate (0.4 ml/kg) and placed in a stereotaxic frame (Kopf, USA). For ICV injections (7PA2 
CM administration), sixteen rats were fitted with a permanently indwelling cannula (23 
gauge) aimed at the lateral cerebral ventricle. Half of the rats in each randomly assigned 
group (experimental and control) received left lateral ventricle cannula implants and the other 
half received right lateral ventricle cannula implants. With the incisor bar set 3.5 mm below 
the interaural line, the stereotaxic coordinates for cannula implantation were 1.0 mm posterior 
and ± 1.5 mm lateral to bregma, and 3.0 mm below the pial surface (Paxinon and Watson, 
1998). Cannula placement and patency was verified by vigorous drinking (>5 ml/20 min) 
following ICV injection of 0.5 µg/ml of angiotensin II (Johnson and Epstein, 1974). 
Following a 7 d recovery period from surgery, the experimental group was injected ICV with 
10 µl of 7PA2 CM and the control group was injected ICV with 10 µl of CHO CM (wild-type 
control), and initial behavioral testing was conducted 2 h following ICV injections. This 
temporal sequence for behavioral testing following 7PA2 CM ICV injections has been 
previously explained, and the effect on memory dissipates within 24 h post-injection (Cleary 
et al., 2005). 
For IH injections (aggregated Aβ1-42 and aggregated NAC61-95) the remaining thirty 
two rats were fitted with permanently indwelling bilateral cannulae aimed at the CA3 region 
of the dorsal hippocampus of the brain, with the incisor bar set 3.5 mm below the interaural 
line, the stereotaxic coordinates were 3.3 mm posterior and ± 2.6 mm lateral to bregma, and 
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3.7 mm below the pial surface (Paxinos and Watson, 1998). Following a 7 d recovery period 
from surgery the rats were randomly assigned to groups. Sixteen rats were assigned to the 
aggregated Aβ1-42 experimental group, of which eight received bilateral IH injection of 
aggregated Aβ1-42 and eight received bilateral IH injection of sterile water, and sixteen rats 
were assigned to the aggregated NAC61-95 group, of which eight received bilateral IH 
injection of aggregated NAC61-95 and eight received bilateral IH injection of sterile water. 
These experimental subjects were injected bilaterally IH with 5 µl (per side) of aggregated 
Aβ1-42 (n=8) and the corresponding control group was injected bilaterally IH with 5 µl (per 
side) of sterile water (n=8), the remaining IH group was injected with bilaterally IH with 5 µl 
(per side) of aggregated NAC61-95 (n=8) and the corresponding control group was injected 
bilaterally IH with 5 µl (per side) of sterile water (n=8). Using a 26 gauge needle connected 
to a Hamilton microsyringe, injectates were deposited slowly over a 15 min period, and the 
injector remained in place for a further 2 min. Sterile water was the used as the control 
injectate because this was the case in other behavioural studies of this nature, and adhering to 
this procedure ensured that the data were comparable to those of previously published 
studies. Ten days after the bilateral IH injections, the collection of behavioral data resumed. 
Data were collected daily from all six cycles of the ALCR schedule for each subject in each 
group. Following the collection of behavioral data from the IH injected groups (aggregated 
Aβ1-42 and aggregated NAC61-95 and their IH injected sterile water control counterparts), these 
rats were then bilaterally injected IH with 1 µl of Evans blue (per side). All of the IH injected 
rats were then deeply anaesthetized and perfused through the ascending aorta with 4% 
paraformaldehyde. Using a cryostat, the brains were then sectioned through the plane of the 
IH microinjection sites and viewed using a light microscope for confirmation of the position 
of each IH injection. 
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Statistical analyses 
The ICV 7PA2 CM vs CHO CM data on incorrect lever perseverations were analysed by t-
test per day (Fig. 1), and the ICV 7PA2 CM RRR data were analysed by repeated measures 
ANOVA (Fig. 2). The aggregated Aβ1-42 vs sterile water data and the aggregated NAC61-95 vs 
sterile water data on incorrect lever perseverations were analysed by t-test (Fig. 3). The RRR 
data (Aβ1-42 and NAC61-95) were analysed by daily t-tests in the first instance for deviation 
from the control condition, and then by repeated measures ANOVA within and between 
groups (Fig. 4, 5). ICV 7PA2 injection effects on memory have previously been shown to last 
for less than 24 hours, and IH aggregated peptide injection effects on memory have 
previously been shown to take approximately 30 days to develop. 
 
RESULTS 
ICV injections of 7PA2 CM produced an acute increase in incorrect lever perseverations (Fig. 
1), indicating a decline in cognitive ability [t=5.33, p<0.001]. This acute effect of 7PA2 CM-
induced synaptotoxicity on behaviour, lasting for less than 1 day, has been previously 
reported (e.g., Cleary et al., 2005). And, ICV 7PA2 CM injection had no acute or chronic (up 
to 50 days post-injection) effect on RRRs within the groups [7PA2 CM; F50,350=1.21, p=0.16 
CHO CM; F50,350=1.11, p=0.18] or between the groups [F1,14=0.01, p=0.90] (Fig. 2). 
Bilateral IH injection of aggregated Aβ1-42, and bilateral IH injection of aggregated 
NAC61-95 produced a chronic increase in incorrect lever perseverations, indicating a decline in 
cognitive ability [Aβ1-42 vs sterile water; t=-24.62, p<0.001: NAC61-95 vs sterile water; t=-
18.89, p<0.001] (Fig 3) from approximately day 30 onward. This finding is consistent with 
the effects of IH aggregated peptide injections on operant behaviour in the rat since its first 
investigation (Cleary et al., 1995), and has previously been reported for IH injections of 
aggregated Aβ1-42 (e.g., O’Hare et al., 1999), and for aggregated NAC61-95 (e.g., Kim et al., 
13 
 
 
 
2009) [Aβ1-42 vs sterile water day 1-29; t=-1.30, p>0.05: NAC61-95 vs sterile water day 1-29; 
t=-1.22, p>0.05]. There were no significant differences in RRRs during approximately the 
first 35 days following bilateral IH injection of aggregated Aβ1-42 (Fig. 4), however RRRs 
increased significantly in the aggregated Aβ1-42 group from this point until the end of the 
study (p’s<0.001). Repeated measures analyses indicated a significant effect within the 
groups by days [Aβ1-42; F80,560=8.93, p<0.001: sterile water; F80,560=4.26, p<0.001] and 
between the groups [F1,14=9.19, p<0.001]. There were no significant differences in RRRs 
during approximately the first 35 days following bilateral IH aggregated NAC61-95 injection 
(Fig. 5), however RRRs increased significantly in the NAC61-95 group from this point until the 
end of the study (p’s<0.01). Repeated measures analyses indicated a significant effect within 
the groups by days [NAC61-95; F80,560=7.76, p<0.001: sterile water; F80,560=3.82, p<0.001] and 
between the groups [F1,14=5.51, p<0.05]. 
 
DISCUSSION 
The current study employed animal models of the two most prevalent forms of 
dementia, AD and DLB (Herbert et al., 2013; Poewe, 2005). In order to establish whether 
acute synaptotoxicity was linked to increased behavioral output, the 7PA2 CM  ICV injection 
model of AD was employed, and in order to determine whether chronic neurotoxicity was 
linked to increased behavioural output the bilateral IH injection model of AD (aggregated 
Aβ1-42), and the bilateral IH injection model of  DLB (aggregated NAC61-95) were employed. 
The chronic IH aggregated peptide injection models were more likely to approximate the 
stage of clinical dementia encountered by physicians at the point of diagnosis of dementia, 
and at the later stages of pathogeneses where agitation might be encountered. 
The current study found that ICV injection of 7PA2 CM produced an acute memory 
deficit, with full recovery at 24 h post injection, as measured by incorrect lever perseverations 
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(Fig. 1), but had no effect on RRRs, even at an extended latency (Fig. 2). This effect of 7PA2 
CM on memory has been reported extensively (e.g., O’Hare et al., 2016) but not the effect on 
RRRs. Bilateral IH injection of aggregated Aβ1-42 and bilateral IH injection of aggregated 
NAC61-95 produced a significant increase in incorrect lever perseverations (Fig. 3), and these 
findings are also in agreement with previous investigations [Aβ1-42 (e.g., O’Hare et al., 1999), 
and NAC61-95 (e.g., O’Hare et al., 2010b)]. Incorrect lever perseverations provide a measure 
of the disruption of reference memory, including general aspects of executive function, 
reasoning, and goal-oriented manipulation of acquired information (Poling et al., 2008; 
Cleary et al., 2005). 
RRRs are generally measured as a safeguard to ensure that decreases in RRRs are not 
misconstrued as direct central nervous system effects. Consequently, they are usually 
measured to provide information on the general state of health of an experimental animal, and 
a fall in RRRs accompanied by a decrease in cognitive ability would indicate that any 
conclusion suggesting central effects might be the result of an experimental confound. IH 
injections of aggregated Aβ1-42 and aggregated NAC61-95 resulted in memory deficits (Fig. 3), 
and RRRs increased following IH injections of aggregated Aβ1-42 (Fig. 4) and aggregated 
NAC61-95 (Fig. 5). These findings indicate that the IH aggregated peptide injection models 
employed here determined detrimental effects on memory function, and associated effects on 
increased behavioral output (agitation). These findings are important because while there is 
one mouse model of AD in which APP23 mice have been found to show memory deficits and 
increased aggressiveness (Vloeberghs et al., 2006), there is very little in the literature of 
preclinical models of dementia that addresses the issue of memory decline and a correlation 
with extraneous problematic behaviors. Yet problem behaviors, such as agitation are highly 
prevalent in dementia, and specific pharmacological interventions that have not been 
screened against overall outcomes for the patient are frequently used in their treatment. 
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A recent review of investigational compounds for the treatment of agitation in 
dementia (Garay et al., 2016) considered the efficacy of drugs in ongoing or newly completed 
clinical trials. This review identified 24 clinical trials, drugs in phase III included an 
antipsychotic, an antidepressant, a novel compound (AVP-786), and a cannabinoid, and in 
phase II scyllo-inositol (ELND005) was likely to progress to phase III. Therefore, some 
headway is being made in this area. Consequently, a preclinical in-vivo screen using 
established procedures for modelling dementia would be of considerable value. Clinically, 
agitation in dementia is frequently observed and can range from constant vocalization, 
wandering, and severe sleep disturbances, but it has not been given the research emphasis 
applied to the basic neurophysiological etiology of memory dysfunction in dementia. 
However, the management of agitation, psychotic and other non-memory related symptoms 
of dementia is a major clinical concern. There is a growing recognition that neuropsychiatric 
symptoms, such as agitation, might increase the rate of progression of dementia. And this is 
particularly relevant to AD, where it has been found that neuropsychiatric symptoms, such as 
psychosis, agitation and aggression were associated with a more rapid progression to severe 
dementia and reduced survival times (Peters et al., 2015). 
A range of pharmacological agents have been employed in attempts to treat 
behavioral problems related to dementia; these include anxiolytic drugs, antidepressant drugs, 
anticonvulsant drugs, α- and β-adrenergic drugs, lithium, hormones, and antipsychotic drugs. 
However, the emphasis of preclinical laboratory-based modelling of dementia has tended to 
concentrate on memory dysfunction, because pharmacological interventions for memory 
dysfunction are seen as a major research target. As a result, extension of the models 
employed to investigate memory to other symptoms commonly reported in the clinical 
literature have largely been overlooked. The findings of the current study indicate that the 
technique of bilateral IH injection of pre-aggregated peptides, aggregated Aβ1-42 as a model 
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of AD and aggregated NAC61-95 as a model of DLB, can be extended to provide a useful in 
vivo animal model of the syndrome of agitation that is commonly associated with cognitive 
decline in dementia. This model could be used to investigate pharmacological interventions 
for agitation, including aggressive behaviors and sleep disturbances associated with the 
disease process. Adopting the preclinical approach to modeling agitation described in the 
current study would present a method for screening drugs that have ameliorative effects on 
emerging problem behaviors, but that do not have detrimental effects on the memory 
functions that have already been compromised by the accumulation of neurotoxic aggregates 
in the brain. 
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Fig. 1. Effect of ICV 7PA2 CM injection on incorrect lever perseverations, data presented as 
means ± SEM (* p<0.001). 
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Fig. 2. Effect of ICV 7PA2 CM injection on running response rates up to 50 days post 
injection, data presented as means ± SEM (repeated measures ANOVA within and between 
groups p’s>0.05). 
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Fig. 3. Effect of bilateral IH injections of aggregated Aβ1-42 and aggregated NAC61-95 in the 
CA3 area of the dorsal hippocampus on incorrect lever perseverations, data presented as 
means ± SEM (* p<0.001). 
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Fig. 4. Effect of bilateral IH injections of aggregated Aβ1-42 in the CA3 area of the dorsal 
hippocampus on running response rates, data presented as means ± SEM (* p<0.001; 
repeated measures ANOVA within and between groups p’s<0.001). 
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Fig. 5. Effect of bilateral IH injections of aggregated NAC61-95 in the CA3 area of the dorsal 
hippocampus on running response rates, data presented as means ± SEM (* p<0.01; repeated 
measures ANOVA within and between groups p<0.001 and p<0.05, respectively). 
 
 
 
